Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 96, Issue 5, 2001, Pages 1448-1454

  Guedon C ^a   Le Cam Duche, V ^a   Lalaude, O ^a   Menard J F ^a   Lerebours, E ^a   Borg, J Y ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; AGED; ARTICLE; AUTOSOMAL INHERITANCE; ENTERITIS; FEMALE; FIBRINOLYSIS; GENE LOCATION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0343807499     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02360-7     Document Type: Article

References (55)

1. Wakefield A.J., Dhillon A.P., Rowles P., et al. Pathogenesis of crohn's disease. multifocal gastrointestinal infarction. Lancet. 2:1989;1057-1062.
2. Talbot R.W., Heppell J., Dozois R.R., et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 61:1986;140-145.
3. Hudson M., Hutton R.A., Wakefield A.J., et al. Evidence for activation of coagulation in crohn's disease. Blood Coag Fibrinol. 3:1992;773-778.
4. De Jong E., Porte R.J., Knot E.A.R., et al. Disturbed fibrinolysis in patients with inflammatory bowel disease. a study in blood plasma, colon mucosa and faeces. Gut. 30:1989;188-194.
5. Gris J.C., Scved J.F., Raffanel C., et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost. 63:1990;472-475.
6. Bargen J.A., Barker N.W. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 58:1937;17-31.
7. Souto J.C., Martinez E., Roca M., et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 40:1995;1883-1889.
8. Jackson L.M., O'Gorman P., O'Connell J., et al. Thrombosis in inflammatory bowel diseases clinical setting, procoagulant profile and factor V Leiden . Q J Med. 90:1997;183-188.
9. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. part III. complications. Gut. 5:1964;1-22.
10. Chamouard P., Grunebaum L., Wiesel M.L., et al. Prevalence and signification of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci. 39:1994;1501-1504.
11. Koutroubakis I.E., Petinaki E., Agnastopoulou E., et al. Anti-cardiolipin, and anti-B2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 43:1998;2507-2512.
12. Aichbichler B.W., Petritsch W., Reicht G.A., et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 44:1999;852-856.
13. Liebman H.A., Kashani R., Sutherland D., et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology. 115:1998;830-834.
14. Novacek G., Miehsler W., Kapiotis S., et al. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol. 94:1999;685-690.
15. Haslam N., Standen G.R., Probert C.S. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 11:1999;1289-1291.
16. Over H.H., Ulgen S., Tuglular S., et al. Thrombophilia and inflammatory bowel disease does factor V mutation have a role? Eur J Gastroenterol Hepatol. 10:1998;827-829.
17. Mahmud N., Molloy A., Mc Partlin J., et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut. 45:1999;389-394.
18. Cattaneo M., Vecchi M., Zighetti M.L., et al. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease a pathogenic link with thromboembolic complications? Thromb Haemost. 80:1998;542-545.
19. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin level and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
20. Zivelin A., Rosenberg N., Faier S., et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 92:1998;1119-1124.
21. Lunghi B., Lacoviello L., Gemmeti D., et al. Detection of new polymorphic markers in factor V gene association with factor V levels in plasma . Thromb Haemost. 75:1996;45-48.
22. Alhenc-Gelas M., Nicaud V., Gandrille S., et al. The factor V gene A4070G mutation, and the risk of venous thrombosis. Thromb Haemost. 81:1999;193-197.
23. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's Disease Activity Index. Gastroenterology. 70:1976;439-444.
24. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. final report on a therapeutic trial. Br Med J 1955: 1041-8.
25. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
26. Alhenc-Gelas M., Le Cam-Duchez V., Emmerich J., et al. The A20210 allele of prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. Blood. 90:1997;1711.
27. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet. 10:1995;111-113.
28. Le Cam-Duchez V., Gandrille S., Tregouet D., et al. Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. Br J Haematol. 106:1999;889-897.
29. Dahlback B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously recognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C . Proc Natl Acad Sci USA. 90:1993;1004-1008.
30. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation. Lancet. 344:(8935):1994;1443-1447.
31. Van Boren H.H., Reitsma P.H., Rosendaal F.R., et al. V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 75:1996;417-421.
32. Gandrille S.G., Greengard J.S., Alhenc-Gelas M., et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood. 86:1995;219-224.
33. Heneghan M.A., Cleary B., Murray M., et al. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci. 43:1998;1356-1361.
34. Koutroubakis I.E., Sfiridaki A., Mouzas I.A., et al. Resistance to activated protein C and low level of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 95:2000;190-194.
35. Akar N., Akar G., Dalgin A., et al. Frequency of factor V (1691G→A) mutation in a Turkish population. Thromb Haemost. 78:1997;1527-1529.
36. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
37. Van der Put N.M.J., Eskes T.K.A.B., Blom H.J. Is the common 677CT mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? a meta-analysis. Q J Med. 90:1997;111-115.
38. Tosetto A., Missiaglia E., Frezzato M., et al. TheVITA project. C677T mutation in the methylenetetrahydrofolate reductase gene and risk of venous thrombosis. Br J Haematol. 97:1997;804-806.
39. 20210 mutation. Thromb Haemost. 79:1998;907-911.
40. 506). Arterioscler Thromb Vasc Biol. 17:1997;1662-1666.
41. Hillarp A., Zøller B., Svensson P.J., et al. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 78:1997;990-992.
42. Arruda V.R., Annichino-Bizzacchi J.M., Gonçalves M.S. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost. 78:1997;1430-1433.
43. Rosendaal F.R., Doggen C.J.M., Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 79:1998;700-706.
44. Reber G., Arvieux J., Comby E., et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. the working group on methodologies in haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose Thrombose). Thromb Haemost. 73:1995;444-452.
45. de Visser M.C.H., Guasch J.F., Kamphuisen P.W., et al. The HR2 haplotype of factor V. effects on factor V levels, normalized APC sensitivity ratios and the risk of venous thrombosis. Thromb Haemost. 203:(suppl):1999;A642.
46. Luddington R., Jackson A., Pannerselvam S., et al. The factor V HR2 haplotype: Risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost. 266:(suppl):1999;A835.
47. Wyshock E., Caldwell M., Crowley J.P. Deep venous thrombosis, inflammatory bowel diseases and protein S deficiency. Am J Clin Pathol. 90:1988;633-635.
48. Lake A.M., Stauffer J.Q., Stuart M.J. Hemostatic alterations in inflammatory bowel disease. response to therapy. Dig Dis Sci. 23:1978;897-902.
49. Knot E., Cate J.W.T., Leeksma O.C., et al. No evidence for a prethrombotic state in stable chronic inflammation bowel disease. J Clin Pathol. 36:1983;1387-1390.
50. Boville E.G., Hasstedt S.J., Leppert M.F., et al. Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost. 82:1999;662-666.
51. Koeleman B.P.C., van Rumpt D., Hamulyak K., et al. Factor V Leiden an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost. 74:1995;580-583.
52. Castoldi E., Kalafatis M., Lunghi B., et al. Molecular bases of pseudo-homozygous APC resistance the compound heterozygosity for fV R506Q and a fV null mutation results in the exclusive presence of FV Leiden molecules in plasma . Thromb Haemost. 80:1998;403-406.
53. Fenton J.W., Ofosu F.A., Brezniak D.V., et al. Thrombin and antithrombotics. Semin Thromb Haemost. 24:1998;87-91.
54. Wakefield T.W., Strieter R.M., Prince M.R., et al. Pathogenesis of venous thrombosis a new insight . Cardiovasc Surgery. 5:1997;6-15.
55. Wakefield T.W., Strieter R.M., Downing L.J., et al. P-selectin, and TNF inhibition reduce venous thrombosis inflammation. J Surg Res. 64:1996;26-31.